ORGANIZATION AND MANAGEMENT

The Bantam management team has extensive leadership experience and proven records in oncology drug discovery and development for bio-pharmaceuticals.

HIGHLIGHTS

Founded 2015
Virtual Company
Patented Technology

SCIENCE ADVISORY BOARD

Prominent industry and academic leaders in oncology drug development and leadership roles

EXPERIENCED TEAM

Deep experience in oncology drug discovery and development

MARKET

$10 billion oncology market opportunity

Bantam operates as a virtual company in a highly cost efficient manner. The Bantam management team has deep experience in oncology drug discovery and development including R&D and partnering. Bantam’s scientific advisory board is comprised of prominent academic and industry leaders with drug development and executive leadership roles in early stage and global pharmaceutical companies.

MANAGEMENT TEAM

MICHAEL LUTHER, PhD, MBA

MICHAEL LUTHER, PhD, MBA

President & CEO

 

  • Former VP drug discovery for both GSK and Merck
  • At GSK and Merck, led teams that progressed new medicines from bench to clinic
  • Experience includes strong operations and business development experience in startups and global biopharmaceutical industry
MATTHEW KOSTURA, PhD

MATTHEW KOSTURA, PhD

Chief Scientific Officer

 

  • Deep drug discovery experience from target validation to proof of concept
  • Includes scientific and management roles in pharma and biotech organizations including Merck, GSK, and TransTech Pharma
ALAN COOPER, PhD

ALAN COOPER, PhD

Head of Chemistry

 

  • Medicinal chemist with extensive experience in drug discovery and development at Schering-Plough and Merck
  • Participated in the discovery of several marketed drugs including Noxafil®, and Lonafarnib®
  • Expertise in oncology, antibacterial, antiviral, and immunology drug discovery

BOARD OF DIRECTORS

 

Michael Luther, PhD, MBA,
President, CEO

Bantam Pharmaceutical

Lionel Goldfrank III
Principal in several private investment companies
Founder of American & Overseas Asset Services Corporation
Formerly with Goldman Sachs

Victor Keen
Of Counsel at Duane Morris, LLP
Co-Chair Caretec Group, Inc (OTC)
Former Board Member Research Frontiers, Inc (NASD)

John Reid
Former Chief Technology Officer for Colgate Palmolive
responsible for Global R&D, IT, and Supply Chain

W. James Tozer, Jr.
Co-owner and Founder Vectra Management Group
Founding Investor in Lending Tree, Vectra Bank Colorado, and Draper Bank
Director in pharma and medical device companies GangaGen, PhotoPharmics, PenBlade

SCIENCE ADVISORY BOARD

 

Briggs Morrison, MD
Managing Partner MPM Capital,
CEO Syndax, Inc.

Mike Patane, PhD
Chief Scientific Officer, Mitobridge;

Pam Cohen, MD
Former Chief Medical Officer at BluePrint Medicines, Novartis

Rainer Fuchs, PhD
Former CIO Harvard Medical School
Biogen & GSK R&D;

Nahum Sonenberg, PhD
Professor, Goodman Cancer Research Centre, McGill University

George Mulligan, PhD
VP Translational Medicine Mitobridge

Mark Manfredi, PhD
CSO, Kyn Therapeutics
EIR Atlas Venture

Jedd Levine, MD, MBA
EVP Clinical Affairs, Oncology Partners